Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis-Reference-Cited by-同舟云学术

Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis

Published:2021-01-02 Issue:1 Volume:28 Page:1-2
ISSN:1350-6129
Container-title:Amyloid
language:en
Short-container-title:Amyloid

Author:

Palladini Giovanni¹,Schönland Stefan O.²,Sanchorawala Vaishali³,Kumar Shaji⁴,Wechalekar Ashutosh⁵,Hegenbart Ute²,Milani Paolo¹,Ando Yukio⁶,Westermark Per⁷,Dispenzieri Angela⁴,Merlini Giampaolo¹

Affiliation:

1. Amyloidosis Research and Treatment Center, Foundation “Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo”, Department of Molecular Medicine, University of Pavia, Pavia, Italy

2. Department V of Internal Medicine, Amyloidosis Center, University Hospital Heidelberg, Heidelberg, Germany

3. School of Medicine and Boston Medical Center, Amyloidosis Center, Boston University, Boston, MA, USA

4. Mayo Clinic, Rochester, MN, USA

5. National Amyloidosis Centre, University College London, London, UK

6. Department of Amyloidosis Research, Faculty of Pharmaceutical Sciences, Nagasaki International University, Sasebo, Japan

7. Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden

Publisher

Informa UK Limited

Subject

Internal Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13506129.2020.1868810

Reference5 articles.

1. New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes

2. Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL)

3. Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis

4. Kastritis E, Palladini G, Minnema M, et al. Subcutaneous daratumumab + cyclophosphamide, bortezomib, and dexamethasone (CYBORD) in patients with newly diagnosed light chain (AL) amyloidosis: primary results from the phase 3 ANDROMEDA study. EHA library. 2020. EHA 2020 meeting abstract.

5. Utility of serum free light chain ratio in response definition in patients with multiple myeloma

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Kidney Transplant Outcomes in Amyloidosis: US National Database Study;Transplantation;2024-08-28

2. Safety and efficacy of B cell maturation antigen‐directed CAR T‐cell therapy in patients with relapsed/refractory multiple myeloma and concurrent light chain amyloidosis;European Journal of Haematology;2024-08-27

3. Redefining Cardiac Involvement and Targets of Treatment in Systemic Immunoglobulin AL Amyloidosis;JAMA Cardiology;2024-08-21

4. Diagnostic performance of liver stiffness as marker of liver involvement in systemic immunoglobulin light chain (AL) amyloidosis;Annals of Hematology;2024-08-16

5. Delayed identification of monoclonal protein is associated with early death in isolated cardiac AL amyloidosis;Amyloid;2024-07-02